Caribou Biosciences Inc. (NASDAQ: CRBU) stock gained by 1.22% at the last close while the CRBU stock price surges by 6.98% in the pre-market trading session. Caribou is a clinical-stage CRISPR genome-editing pharmaceutical business devoted to improving the lives of patients with severe illnesses by developing next-generation genome-edited cell treatments using the company’s patented chRDNA technology.
CRBU stock’ Recent Past Development
Ran Zheng has been named to Caribou Biosciences’ board of directors. Ms. Zheng has over 25 years of experience in the biotechnology sector as a pioneer in biologics drug development, as well as a wide understanding of technical operations and gene and cell therapy manufacturing.
Ms. Zheng is the CEO and a member of the board of directors of Landmark Bio, which is a public benefit limited liability company founded to speed up the development of transformational new medicines by converting today’s cutting-edge research into tomorrow’s ground-breaking treatments. To allow and expedite medication discovery and biomedical innovation, Landmark Bio focuses on new technologies, such as cell and gene treatments, mRNA, and other innovative modalities. Ms. Zheng most recently worked as a chief technical officer at Orchard Therapeutics, a commercial-stage global gene therapy business specialized in hematopoietic stem cell-based gene treatments, before entering Landmark Bio earlier this year.
Rachel Haurwitz, Caribou’s president and CEO stated,
It delighted him to welcome Ran to the board of directors. From engineering and process development to manufacturing and supply chain management, Ran provides a wealth of strategic and operational knowledge in the production of gene and cell treatments. As they progress their chRDNA-edited allogeneic CAR-T and CAR-NK cell treatments for the possible therapy of difficult hematologic malignancies and solid tumors, they look forward to gaining insight and expertise from her.
Ms. Zheng commented,
Caribou has created a novel and differentiated genome-editing method that allows them to produce a pipeline of off-the-shelf allogeneic cell treatments with improved persistence and anti-tumor efficacy. Caribou’s research into allogeneic cell treatments has the potential to make a significant difference in the lives of individuals suffering from severe illnesses. Caribou is unquestionably a leader in this sector, and he is honored to be a member of its board of directors.